Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington’s disease treatment and accused it of lying

2026-03-06 01:45:49

The FDA is already under fire from lawmakers for recent delays and rejections of new drugs for rare diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes